AtriCure, Inc. (NASDAQ: ATRC)

AtriCure, Inc. (NASDAQ: ATRC), a medical device company, is focused on leading the development, manufacturing and selling of novel cardiac surgical ablation systems intended to create precise lesions, or scars, in cardiac tissue. The FDA has approved the AtriCure Isolator® system, including its Isolator SynergyTM ablation clamps, and AtriCure’s multifunctional pen and CoolrailTM linear ablation device, for the destruction of heart tissue during surgical procedures. For further information, visit the Company’s web site at www.atricure.com.